Full Text
Secukinumab vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from a Brazilian Perspective

Abstract

Authors

N Lopes C Suzuki M Barbeau A MacPherson SM Jugl

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×